Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GMAB
GENMAB A/S
NASDAQ
$33.23
▼ DOWN 2.55% (-0.87)

KEY STATISTICS

Market Cap$20.40 B
52w High$35.43
52w Low$23.62
Dividend Yield—
Frequency—
P/E25.04
Volume1.51M
Shares Out.613.94M

COMPANY

LEADERSHIP

Jan van de Winkel
CHIEF EXECUTIVE
Jan van de Winkel

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 1, 2009
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
3,119

PRICE TARGET

Target High$43.00
Target Low$32.00
Target Median$39.00
Target Consensus$38.25

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.21B
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2018-05-01Forward5:1

PRICE

$33.23 ▼ DOWN 2.55% (−$0.87)
OVERLAYS
$33.25$33.50$33.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM33.23

About Genmab A/S

https://www.genmab.com ↗

Genmab A/S, based in Denmark, develops antibody therapeutics for cancer and other diseases, with marketed products like DARZALEX and teprotumumab, and a broad pipeline including Phase 2 and preclinical programs through collaborations worldwide.

INDUSTRY

Biotechnology

A PRODUCT GENMAB A/S IS KNOWN FOR

EPKINLY® (epcoritamab-bysp)
EPKINLY® (epcoritamab-bysp)

An injectable prescription medicine for adults with certain relapsed or refractory large B-cell and follicular lymphoma, exemplifying Genmab’s successful development of innovative antibody therapies.

COMPETITORS

COMPETITOR
ADCT COMPARE
AMGN COMPARE
INCY COMPARE
REGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
51
LISTED HERE
15
RANKED BY POSITION SIZE
IBB
1.23% · 3.9M
FBT
3.56% · 3.1M
AVDE
0.10% · 546.8K
CANC
2.88% · 183.4K
CN
CNCR
3.42% · 35.8K
APIE
0.09% · 33.0K
ONEQ
0.01% · 26.1K
DFAI
0.00% · 15.3K
HELX
0.54% · 5.1K
JHMD
0.17% · 5.0K
IBBQ
0.16% · 4.7K
WBIO.L
0.45% · 4.5K
NIFE
3.42% · 3.6K
BIB
0.09% · 2.7K
PXUS
0.16% · 49

INSTITUTIONAL OWNERSHIP

SHARES OWNED
13.34%
HOLDERS
420
TOP 12 OF 420 · RANKED BY POSITION SIZE
Orbis Allan Gray Ltd
14.4M sh · $444.09M
Paradigm Biocapital Advisors LP
13.1M sh · $360.77M
Alliancebernstein L.P.
11.0M sh · $335.96M
Deerfield Management Company, L.P. (Series C)
6.9M sh · $188.58M
Deep Track Capital, LP
5.7M sh · $155.21M
Blackrock Inc.
5.1M sh · $127.67M
Arrowstreet Capital, Limited Partnership
5.0M sh · $153.32M
Blackrock, Inc.
4.7M sh · $128.32M
Renaissance Technologies LLC
4.4M sh · $118.44M
Waddell & Reed Financial Inc
4.2M sh · $136.56M
Sofinnova Investments, Inc.
4.0M sh · $111.12M
Two Sigma Investments, LP
3.5M sh · $96.33M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity4
Return On Assets4
Debt To Equity1
Price To Earnings2
Price To Book2
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Josh Gottheimer
Josh Gottheimer
Purchase
2025-01-16
 Daniel Goldman
Daniel Goldman
Sale
2023-07-10
SENATE TRADES
Thomas R. Carper
Thomas R. Carper
Purchase
2020-11-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
4 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY TD Cowen BUY HC Wainwright & Co. BUY Truist Securities BUY

SECTORS PEERS

PEERPRICE
ILMN$215.59COMPARE
RPRX$60.85COMPARE
DGX$242.76COMPARE
INCY$124.37COMPARE
ROIV$34.71COMPARE
UTHR$515.46COMPARE
THC$266.80COMPARE
ZBH$100.91COMPARE